Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The Role of Checkpoint Inhibitors in Glioblastoma.

Desai K, Hubben A, Ahluwalia M.

Target Oncol. 2019 Aug;14(4):375-394. doi: 10.1007/s11523-019-00655-3. Review.

PMID:
31290002
2.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

3.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
4.

An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Neagu MR, Reardon DA.

Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3. Review.

PMID:
26454859
5.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

6.

Immune Checkpoint in Glioblastoma: Promising and Challenging.

Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J.

Front Pharmacol. 2017 May 9;8:242. doi: 10.3389/fphar.2017.00242. eCollection 2017. Review.

7.

Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.

Yeo AT, Charest A.

J Cell Biochem. 2017 Sep;118(9):2516-2527. doi: 10.1002/jcb.25948. Epub 2017 May 3. Review.

8.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

9.

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Polivka J Jr, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, Pivovarcikova K, Treskova I.

Anticancer Res. 2017 Jan;37(1):21-33. Review.

PMID:
28011470
10.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
11.

Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.

Ă–zdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.

Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19. Review.

PMID:
29056275
12.

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas.

Nesseler JP, Schaue D, McBride WH, Lee MH, Kaprealian T, Niclou SP, Nickers P.

Adv Radiat Oncol. 2018 Nov 20;4(2):268-282. doi: 10.1016/j.adro.2018.11.005. eCollection 2019 Apr-Jun. Review.

13.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
14.

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, Dhermain F.

Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Review. French.

PMID:
27032303
15.

Future perspectives in cancer immunotherapy.

Tsiatas M, Mountzios G, Curigliano G.

Ann Transl Med. 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14.

16.

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.

Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J.

J Exp Clin Cancer Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. Review.

17.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012. Epub 2016 Jul 27. Review.

18.

From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Madden DL.

Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5. Review.

PMID:
29411148
19.

Current State of Immunotherapy for Treatment of Glioblastoma.

McGranahan T, Therkelsen KE, Ahmad S, Nagpal S.

Curr Treat Options Oncol. 2019 Feb 21;20(3):24. doi: 10.1007/s11864-019-0619-4. Review.

20.

Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.

Mooney J, Bernstock JD, Ilyas A, Ibrahim A, Yamashita D, Markert JM, Nakano I.

World Neurosurg. 2019 Sep;129:90-100. doi: 10.1016/j.wneu.2019.05.205. Epub 2019 May 29. Review.

PMID:
31152883

Supplemental Content

Support Center